Literature DB >> 30318742

Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma.

Christopher DeRenzo1, Catherine Lam2, Carlos Rodriguez-Galindo2, Louis Rapkin3, Stephen Gottschalk1, Rajkumar Venkatramani1.   

Abstract

There is no established salvage regimen for pediatric patients with relapsed nasopharyngeal carcinoma (NPC) and outcomes are dismal. We performed a multicenter retrospective review to determine outcomes after first salvage therapy for pediatric patients with relapsed NPC. Fourteen patients were treated with varied regimens. Two of the 14 patients received oxaliplatin-containing regimens and achieved a long-term complete response. Although definitive recommendations cannot be made based on outcomes for 14 patients who received varied regimens, we discuss justification for an oxaliplatin-containing regimen in combination with gemcitabine as a reasonable choice for first-line salvage therapy for pediatric patients with relapsed NPC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  NPC; chemotherapy; nasopharyngeal carcinoma; pediatric; relapse

Mesh:

Year:  2018        PMID: 30318742      PMCID: PMC6249063          DOI: 10.1002/pbc.27469

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

1.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

Authors:  O Rixe; W Ortuzar; M Alvarez; R Parker; E Reed; K Paull; T Fojo
Journal:  Biochem Pharmacol       Date:  1996-12-24       Impact factor: 5.858

Review 2.  Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved?

Authors:  Victor Lee; Dora Kwong; To-Wai Leung; Ka-On Lam; Chi-Chung Tong; Anne Lee
Journal:  Crit Rev Oncol Hematol       Date:  2017-04-02       Impact factor: 6.312

3.  A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project.

Authors:  Michela Casanova; Gianni Bisogno; Lorenza Gandola; Giovanni Cecchetto; Andrea Di Cataldo; Eleonora Basso; Paolo Indolfi; Paolo D'Angelo; Francesca Favini; Paola Collini; Paolo Potepan; Andrea Ferrari
Journal:  Cancer       Date:  2011-09-14       Impact factor: 6.860

4.  Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma.

Authors:  Daniel Ka Leung Cheuk; Catherine A Billups; Michael G Martin; Cynthia R Roland; Raul C Ribeiro; Matthew J Krasin; Carlos Rodriguez-Galindo
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

5.  Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study.

Authors:  Enis Ozyar; Ugur Selek; Siddihartha Laskar; Omer Uzel; Yavuz Anacak; Miriam Ben-Arush; Sopiha Polychronopoulou; Fadime Akman; Suzanne L Wolden; Süreyya Sarihan; Robert C Miller; Mahmut Ozsahin; Ufuk Abacioğlu; Margarita Martin; Murat Caloglu; Luciano Scandolaro; Eva Szutowicz; Ibtisam Lale Atahan
Journal:  Radiother Oncol       Date:  2006-09-11       Impact factor: 6.280

6.  Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Sravya Ennamuri; Claudia Gerken; Teresita T Lopez; M Helen Huls; Andrea Sheehan; Meng-Fen Wu; Hao Liu; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

7.  Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.

Authors:  Martina Buehrlen; Christian Michel Zwaan; Bernd Granzen; Lisa Lassay; Peter Deutz; Peter Vorwerk; Gundula Staatz; Günther Gademann; Hans Christiansen; Foppe Oldenburger; Miriam Tamm; Rolf Mertens
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

8.  A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors.

Authors:  Leo Mascarenhas; Marcio Malogolowkin; Saro H Armenian; Richard Sposto; Rajkumar Venkatramani
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

9.  Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: Radiotherapy dose adaptation after chemotherapy response to minimize late effects.

Authors:  Daniel Orbach; Hervé Brisse; Sylvie Helfre; Jerzy Klijanienko; Danielle Bours; Véronique Mosseri; José Rodriguez
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

10.  International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.

Authors:  Michela Casanova; Enis Özyar; Catherine Patte; Daniel Orbach; Andrea Ferrari; Christine Veyrat-Follet; Hassan Errihani; Jianji Pan; Li Zhang; Liji Shen; Krzysztof J Grzegorzewski; Ali Varan
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-14       Impact factor: 3.333

View more
  1 in total

Review 1.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.